C12N 2740/16011
Human immunodeficiency virus, hiv
Official title: Human Immunodeficiency Virus, HIV
C12N2740/16011 (Human immunodeficiency virus, hiv) appears on 3,789 US grants and 5,727 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,789
- Published applications
- 5,727
- Assignees
- 2,226
- Inventors
- 10,234
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 11 | 0 |
| 1989 | 9 | 0 |
| 1990 | 10 | 0 |
| 1991 | 25 | 0 |
| 1992 | 34 | 0 |
| 1993 | 33 | 0 |
| 1994 | 38 | 0 |
| 1995 | 30 | 0 |
| 1996 | 72 | 0 |
| 1997 | 116 | 0 |
| 1998 | 178 | 0 |
| 1999 | 131 | 0 |
| 2000 | 133 | 0 |
| 2001 | 126 | 26 |
| 2002 | 111 | 140 |
| 2003 | 112 | 251 |
| 2004 | 79 | 201 |
| 2005 | 68 | 208 |
| 2006 | 87 | 197 |
| 2007 | 84 | 138 |
| 2008 | 75 | 165 |
| 2009 | 109 | 172 |
| 2010 | 90 | 198 |
| 2011 | 94 | 174 |
| 2012 | 99 | 166 |
| 2013 | 84 | 118 |
| 2014 | 104 | 152 |
| 2015 | 104 | 158 |
| 2016 | 99 | 194 |
| 2017 | 116 | 178 |
| 2018 | 147 | 224 |
| 2019 | 150 | 274 |
| 2020 | 142 | 266 |
| 2021 | 137 | 335 |
| 2022 | 142 | 398 |
| 2023 | 154 | 351 |
| 2024 | 164 | 427 |
| 2025 | 171 | 385 |
| 2026 | 117 | 231 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/16111Concerning hiv envIndexing code1,582
- C12N 2740/16041Use of virus, viral particle or viral elements as a vectorIndexing code1,026
- C12N 2740/16211Concerning hiv gagpolIndexing code956
- C12N 2740/16311Concerning hiv regulatory proteinsIndexing code613
- C12N 2740/16034Use of virus or viral component as vaccineIndexing code400
- C12N 2740/16022New viral proteins or individual genes, new structural or functional aspects ofIndexing code341
- C12N 2740/16051Methods of production or purification of viral materialIndexing code248
- C12N 2740/16021Viruses as suchIndexing code146
All 15 subgroupsShow fewer
- C12N 2740/16061Methods of inactivation or attenuationIndexing code129
- C12N 2740/16023Virus like particles [vlp]Indexing code124
- C12N 2740/16071Demonstrated in vivo effectIndexing code55
- C12N 2740/16033Use of viral protein as therapeutic agent other than vaccineIndexing code52
- C12N 2740/16032Use of virus as therapeutic agent, other than vaccineIndexing code19
- C12N 2740/16031Uses of virus other than therapeutic or vaccineIndexing code8
- C12N 2740/16088For redistributionIndexing code2
Recent patents
- Immune cells with enhanced cytotoxicity and methods of use thereof29 Sep 2026US 12,747,443 B2Ludwig Institute for Cancer Research
- Self-inactivating lentiviral vector comprising a FoxP3 expression cassette29 Sep 2026US 12,747,454 B2The Board of Trustees of the Leland Stanford Junior University
- HIV viral load testing29 Sep 2026US 12,748,120 B2Diagnostics for the Real World, Ltd.
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof15 Sep 2026US 12,735,471 B2iCell Gene Therapeutics Inc.
- Cell surface engineered of tailored therapeutic gene delivery8 Oct 2026US 2026/0308617 A1The Children’s Hospital of Philadelphia
- Retroviral vectors8 Oct 2026US 2026/0308619 A1UCL Business PLC
- Rapamycin resistant cells8 Oct 2026US 2026/0308637 A1Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Improved alum-anchored immunogens1 Oct 2026US 2026/0295039 A1Massachusetts Institute of Technology
- Recombinant enzyme for the accurate insertion of dna sequences in eukaryotic cells1 Oct 2026US 2026/0297624 A1Rensselaer Polytechnic Institute
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Delivery of exogenous DNA sequences in a mammal1,218US 5,580,859 AVical Incorporated · 1996
- Induction of a protective immune response in a mammal by injecting a DNA sequence885US 5,589,466 AVical Incorporated · 1996
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997